Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 5/2016

01.06.2016 | Methotrexat | CME

Psoriasisarthritis

Übersicht medikamentöser Therapieoptionen und Anwendungsbesonderheiten

verfasst von: F. Behrens, D. Thaçi, Prof. Dr. J. Wollenhaupt, K. Krüger

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Psoriasisarthritis, eine chronisch entzündliche Erkrankung des Bewegungsapparates mit Assoziation zur Psoriasis der Haut, zeichnet sich durch ein variables klinisches Bild mit sehr heterogener Krankheitsbelastung der Patienten aus. Klinische Manifestationen umfassen im Wesentlichen Haut- und Nagelveränderungen, periphere Arthritis, Enthesitis, Daktylitis und/oder Wirbelsäulenbefall. Diese Variabilität bedingt eine individuelle Therapie des Patienten mit unterschiedlichen Therapiezielen. Außer internationalen Leitlinien liegen für die Behandlung der Psoriasisarthritis in Deutschland keine Therapieempfehlungen vor. Aus diesem Grund werden in der vorliegenden Arbeit die gesicherten Punkte, Besonderheiten und zu beachtende Aspekte in der Therapie der Psoriasisarthritis in Deutschland unter Berücksichtigung der verschiedenen Hauptformen der Erkrankung zusammengefasst.
Literatur
1.
Zurück zum Zitat Mease P (2006) Management of Psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 8:348–354CrossRefPubMed Mease P (2006) Management of Psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 8:348–354CrossRefPubMed
2.
Zurück zum Zitat Reich K, Krüger K, Mössner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040–1047CrossRefPubMed Reich K, Krüger K, Mössner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040–1047CrossRefPubMed
3.
Zurück zum Zitat Helliwell PS, Taylor WJ (2005) Classification and diagnostic criteria for Psoriatic arthritis. Ann Rheum Dis 64(Suppl 2):ii3–ii8PubMedPubMedCentral Helliwell PS, Taylor WJ (2005) Classification and diagnostic criteria for Psoriatic arthritis. Ann Rheum Dis 64(Suppl 2):ii3–ii8PubMedPubMedCentral
4.
Zurück zum Zitat Coates LC, Kavanaugh A, Mease PJ et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis: Treatment recommendations for psoriatic arthritis 2015. Arthritis Rheum: doi:10.1002/art.39573 Coates LC, Kavanaugh A, Mease PJ et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis: Treatment recommendations for psoriatic arthritis 2015. Arthritis Rheum: doi:10.1002/art.39573
5.
Zurück zum Zitat Gossec L, Smolen JS, Ramiro S et al (2015) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis: doi:10.1136/annrheumdis-2015–208337 Gossec L, Smolen JS, Ramiro S et al (2015) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis: doi:10.1136/annrheumdis-2015–208337
7.
Zurück zum Zitat Augustin M, Schäfer I, Reich K et al (2011) Systemic treatment with corticosteroids in Psoriasis-health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges 9:833–838PubMed Augustin M, Schäfer I, Reich K et al (2011) Systemic treatment with corticosteroids in Psoriasis-health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges 9:833–838PubMed
8.
Zurück zum Zitat Brenner M, Molin S, Ruebsam K et al (2009) Generalized pustular Psoriasis induced by systemic glucocorticosteroids: Four cases and recommendations for treatment. Br J Dermatol 161:964–966CrossRefPubMed Brenner M, Molin S, Ruebsam K et al (2009) Generalized pustular Psoriasis induced by systemic glucocorticosteroids: Four cases and recommendations for treatment. Br J Dermatol 161:964–966CrossRefPubMed
9.
Zurück zum Zitat Mrowietz U, Domm S (2013) Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol 27:1022–1025CrossRefPubMed Mrowietz U, Domm S (2013) Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol 27:1022–1025CrossRefPubMed
10.
Zurück zum Zitat Hellgren L (1976) Induction of generalized pustular psoriasis by topical use of betamethasone-dipropionate ointment in psoriasis. Ann Clin Res 8:317–319PubMed Hellgren L (1976) Induction of generalized pustular psoriasis by topical use of betamethasone-dipropionate ointment in psoriasis. Ann Clin Res 8:317–319PubMed
11.
Zurück zum Zitat Eder L, Chandran V, Ueng J et al (2010) Predictors of response to intra-articular steroid injection in Psoriatic arthritis. Rheumatology 49:1367–1373CrossRefPubMed Eder L, Chandran V, Ueng J et al (2010) Predictors of response to intra-articular steroid injection in Psoriatic arthritis. Rheumatology 49:1367–1373CrossRefPubMed
12.
Zurück zum Zitat Kingsley GH, Kowalczyk A, Taylor H et al (2012) A randomized placebo-controlled trial of methotrexate in Psoriatic arthritis. Rheumatology 51:1368–1377CrossRefPubMedPubMedCentral Kingsley GH, Kowalczyk A, Taylor H et al (2012) A randomized placebo-controlled trial of methotrexate in Psoriatic arthritis. Rheumatology 51:1368–1377CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Coates L, Moverley A, McParland L et al (2014) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomized controlled trial. Lancet 386:2489–2498CrossRef Coates L, Moverley A, McParland L et al (2014) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomized controlled trial. Lancet 386:2489–2498CrossRef
14.
Zurück zum Zitat Baranauskaite A, Raffayova H, Kungurov NV et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of Psoriatic arthritis in methotrexate-naive patients: The RESPOND study. Ann Rheum Dis 71:541–548CrossRefPubMed Baranauskaite A, Raffayova H, Kungurov NV et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of Psoriatic arthritis in methotrexate-naive patients: The RESPOND study. Ann Rheum Dis 71:541–548CrossRefPubMed
15.
Zurück zum Zitat Behrens F, Finkenwirth C, Pavelka K, S̆tolfa J, S̆ipek-Dolnicar A, Thaçi D et al (2013) Leflunomide in Psoriatic arthritis: Results from a large European prospective observational study. Arthritis Care Res 65:464–470CrossRef Behrens F, Finkenwirth C, Pavelka K, S̆tolfa J, S̆ipek-Dolnicar A, Thaçi D et al (2013) Leflunomide in Psoriatic arthritis: Results from a large European prospective observational study. Arthritis Care Res 65:464–470CrossRef
16.
Zurück zum Zitat Kaltwasser JP, Nash P, Gladman D et al (2004) Efficacy and safety of leflunomide in the treatment of Psoriatic arthritis and Psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939–1950CrossRefPubMed Kaltwasser JP, Nash P, Gladman D et al (2004) Efficacy and safety of leflunomide in the treatment of Psoriatic arthritis and Psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939–1950CrossRefPubMed
17.
Zurück zum Zitat Nash P, Thaçi D, Behrens F et al (2006) Leflunomide improves Psoriasis in patients with Psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212:238–249CrossRefPubMed Nash P, Thaçi D, Behrens F et al (2006) Leflunomide improves Psoriasis in patients with Psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212:238–249CrossRefPubMed
18.
Zurück zum Zitat Ho VC, Griffiths CE, Albrecht G et al (1999) Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1‑year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 141:283–291CrossRefPubMed Ho VC, Griffiths CE, Albrecht G et al (1999) Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1‑year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 141:283–291CrossRefPubMed
19.
Zurück zum Zitat Acosta Felquer ML, Coates LC, Soriano ER et al (2014) Drug therapies for peripheral joint disease in Psoriatic arthritis: A systematic review. J Rheumatol 41:2277–2285CrossRefPubMed Acosta Felquer ML, Coates LC, Soriano ER et al (2014) Drug therapies for peripheral joint disease in Psoriatic arthritis: A systematic review. J Rheumatol 41:2277–2285CrossRefPubMed
20.
Zurück zum Zitat Clegg DO, Reda DJ, Mejias E et al (1996) Comparison of sulfasalazine and placebo in the treatment of Psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39:2013–2020CrossRefPubMed Clegg DO, Reda DJ, Mejias E et al (1996) Comparison of sulfasalazine and placebo in the treatment of Psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39:2013–2020CrossRefPubMed
21.
Zurück zum Zitat Fagerli KM, Lie E, Heijde D van der et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73:132–137CrossRefPubMed Fagerli KM, Lie E, Heijde D van der et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73:132–137CrossRefPubMed
22.
Zurück zum Zitat Behrens F, Köhm M, Arndt U et al (2016) Does Concomitant Methotrexate with Adalimumab influence treatment outcomes in patients with Psoriatic arthritis? data from a large observational study. J Rheumatol 43:632–639CrossRefPubMed Behrens F, Köhm M, Arndt U et al (2016) Does Concomitant Methotrexate with Adalimumab influence treatment outcomes in patients with Psoriatic arthritis? data from a large observational study. J Rheumatol 43:632–639CrossRefPubMed
23.
Zurück zum Zitat McInnes IB, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active Psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780–789CrossRefPubMed McInnes IB, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active Psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780–789CrossRefPubMed
24.
Zurück zum Zitat McInnes IB, Mease PJ, Kirkham B et al (2015) Secukinumab, a human anti-interleukin-17 A monoclonal antibody, in patients with Psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386:1137–1146CrossRefPubMed McInnes IB, Mease PJ, Kirkham B et al (2015) Secukinumab, a human anti-interleukin-17 A monoclonal antibody, in patients with Psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386:1137–1146CrossRefPubMed
25.
Zurück zum Zitat Nast A, Boehncke WH, Mrowietz U et al (2011) S3-Leitlinie zur Therapie der Psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges 9(Suppl 2):S1–S104PubMed Nast A, Boehncke WH, Mrowietz U et al (2011) S3-Leitlinie zur Therapie der Psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges 9(Suppl 2):S1–S104PubMed
26.
Zurück zum Zitat Scarpa R, Peluso R, Atteno M et al (2008) The effectiveness of a traditional therapeutical approach in early Psoriatic arthritis: Results of a pilot randomised 6‑month trial with methotrexate. Clin Rheumatol 27:823–826CrossRefPubMed Scarpa R, Peluso R, Atteno M et al (2008) The effectiveness of a traditional therapeutical approach in early Psoriatic arthritis: Results of a pilot randomised 6‑month trial with methotrexate. Clin Rheumatol 27:823–826CrossRefPubMed
27.
Zurück zum Zitat Schiff MH, Jaffe JS, Freundlich B (2014) Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73:1549–1551CrossRefPubMedPubMedCentral Schiff MH, Jaffe JS, Freundlich B (2014) Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73:1549–1551CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Fraser AD, Kuijk AW van, Westhovens R et al (2005) A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active Psoriatic arthritis. Ann Rheum Dis 64:859–864CrossRefPubMed Fraser AD, Kuijk AW van, Westhovens R et al (2005) A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active Psoriatic arthritis. Ann Rheum Dis 64:859–864CrossRefPubMed
29.
Zurück zum Zitat Kavanaugh A, Mease PJ, Gomez-Reino JJ et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020–1026CrossRefPubMedPubMedCentral Kavanaugh A, Mease PJ, Gomez-Reino JJ et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020–1026CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Van der Heijde D, Landewe RBM, Mease P et al (2014) Secukinumab, a monoclonal antibody to interleukin-17 A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: A phase 3 randomized, double-blind, placebo-controlled study. Arthritis Rheum 66(Suppl):S424–954 Van der Heijde D, Landewe RBM, Mease P et al (2014) Secukinumab, a monoclonal antibody to interleukin-17 A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: A phase 3 randomized, double-blind, placebo-controlled study. Arthritis Rheum 66(Suppl):S424–954
31.
Zurück zum Zitat Orbai AM, Weitz J, Siegel EL et al (2014) Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol 41:2290–2294CrossRefPubMed Orbai AM, Weitz J, Siegel EL et al (2014) Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol 41:2290–2294CrossRefPubMed
32.
Zurück zum Zitat Brockbank JE, Stein M, Schentag CT et al (2005) Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 64:188–190CrossRefPubMed Brockbank JE, Stein M, Schentag CT et al (2005) Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 64:188–190CrossRefPubMed
33.
Zurück zum Zitat Kaeley GS (2013) Ultrasound imaging module: report from the GRAPPA 2012 annual meeting. J Rheumatol 40:1450–1452CrossRefPubMed Kaeley GS (2013) Ultrasound imaging module: report from the GRAPPA 2012 annual meeting. J Rheumatol 40:1450–1452CrossRefPubMed
34.
Zurück zum Zitat Mease PJ, Fleischmann R, Deodhar AA et al (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48–55CrossRefPubMed Mease PJ, Fleischmann R, Deodhar AA et al (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48–55CrossRefPubMed
35.
Zurück zum Zitat Antoni CE, Kavanaugh A, Heijde D van der et al (2008) Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35:869–876PubMed Antoni CE, Kavanaugh A, Heijde D van der et al (2008) Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35:869–876PubMed
36.
Zurück zum Zitat Kavanaugh A, Krueger GG, Beutler A et al (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment:Results from the IMPACT 2 trial. Ann Rheum Dis 66:498–505CrossRefPubMed Kavanaugh A, Krueger GG, Beutler A et al (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment:Results from the IMPACT 2 trial. Ann Rheum Dis 66:498–505CrossRefPubMed
37.
Zurück zum Zitat Kavanaugh A, Heijde D van der, McInnes IB et al (2012) Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 64:2504–2517CrossRefPubMed Kavanaugh A, Heijde D van der, McInnes IB et al (2012) Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 64:2504–2517CrossRefPubMed
38.
Zurück zum Zitat Kavanaugh A, Mease P (2012) Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol 89(Suppl):90–93 Kavanaugh A, Mease P (2012) Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol 89(Suppl):90–93
39.
Zurück zum Zitat Sterry W, Ortonne JP, Kirkham B et al (2010) Comparison of two etanercept regimens for treatment of Psoriasis and Psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340:c147CrossRefPubMed Sterry W, Ortonne JP, Kirkham B et al (2010) Comparison of two etanercept regimens for treatment of Psoriasis and Psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340:c147CrossRefPubMed
40.
Zurück zum Zitat Genovese MC, Mease PJ, Thomson GT et al (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34:1040–1050PubMed Genovese MC, Mease PJ, Thomson GT et al (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34:1040–1050PubMed
41.
Zurück zum Zitat Mease PJ, Ory P, Sharp JT et al (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2‑year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68:702–709CrossRefPubMed Mease PJ, Ory P, Sharp JT et al (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2‑year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68:702–709CrossRefPubMed
42.
Zurück zum Zitat Nash P, Lubrano E, Cauli A et al (2014) Updated guidelines for the management of axial disease in psoriatic arthritis. J Rheumatol 41:2286–2289CrossRefPubMed Nash P, Lubrano E, Cauli A et al (2014) Updated guidelines for the management of axial disease in psoriatic arthritis. J Rheumatol 41:2286–2289CrossRefPubMed
43.
Zurück zum Zitat Antoni CE, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 52:1227–1236CrossRefPubMed Antoni CE, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 52:1227–1236CrossRefPubMed
44.
Zurück zum Zitat Braun J, Rudwaleit M, Kary S et al (2010) Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Rheumatology 49:1578–1589CrossRefPubMed Braun J, Rudwaleit M, Kary S et al (2010) Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Rheumatology 49:1578–1589CrossRefPubMed
45.
Zurück zum Zitat Kavanaugh A, McInnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986CrossRefPubMed Kavanaugh A, McInnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986CrossRefPubMed
46.
Zurück zum Zitat Lubrano E, Spadaro A, Marchesoni A et al (2011) The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 29:80–84PubMed Lubrano E, Spadaro A, Marchesoni A et al (2011) The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 29:80–84PubMed
48.
Zurück zum Zitat Mrowietz U, Rostami-Yazdi M, Neureither M et al (2009) 15 Jahre Fumaderm®: Fumarsäureester für die systemische Behandlung der mittelschweren und schweren Psoriasis vulgaris. J Dtsch Dermatol Ges 7(Suppl 2):S3–S16CrossRefPubMed Mrowietz U, Rostami-Yazdi M, Neureither M et al (2009) 15 Jahre Fumaderm®: Fumarsäureester für die systemische Behandlung der mittelschweren und schweren Psoriasis vulgaris. J Dtsch Dermatol Ges 7(Suppl 2):S3–S16CrossRefPubMed
49.
Zurück zum Zitat Chandran V, Schentag CT, Gladman DD (2008) Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort. J Rheumatol 35:469–471PubMed Chandran V, Schentag CT, Gladman DD (2008) Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort. J Rheumatol 35:469–471PubMed
50.
Zurück zum Zitat Reich K, Papp KA, Kerckhoff P van de et al (2015) Efficacy of apremilast sustained through week 52 in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: Results from the LIBERATE study Congress of the Eur Acad Dermatol Venereol. (Abstract LB-010) Reich K, Papp KA, Kerckhoff P van de et al (2015) Efficacy of apremilast sustained through week 52 in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: Results from the LIBERATE study Congress of the Eur Acad Dermatol Venereol. (Abstract LB-010)
51.
Zurück zum Zitat Griffiths CEM, Strober BE, Kerkhof P van de et al (2010) Comparison of Ustekinumab and Etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128CrossRefPubMed Griffiths CEM, Strober BE, Kerkhof P van de et al (2010) Comparison of Ustekinumab and Etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128CrossRefPubMed
52.
Zurück zum Zitat Langley RG, Elewski BE, Lebwohl M et al (2014) Secukinumab in plaque psoriasis: results of two phase three trials. New Engl J Med 371:326–338CrossRefPubMed Langley RG, Elewski BE, Lebwohl M et al (2014) Secukinumab in plaque psoriasis: results of two phase three trials. New Engl J Med 371:326–338CrossRefPubMed
53.
Zurück zum Zitat Thaçi D, Blauvelt A, Reich K et al (2015) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73:400–409CrossRefPubMed Thaçi D, Blauvelt A, Reich K et al (2015) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73:400–409CrossRefPubMed
54.
Zurück zum Zitat Armstrong AW, Tuong W, Love TJ et al (2014) Treatments for nail psoriasis: A systematic review by the GRAPPA Nail Psoriasis Work Group. J Rheumatol 41:2306–2314CrossRefPubMed Armstrong AW, Tuong W, Love TJ et al (2014) Treatments for nail psoriasis: A systematic review by the GRAPPA Nail Psoriasis Work Group. J Rheumatol 41:2306–2314CrossRefPubMed
55.
Zurück zum Zitat Rich P, Gooderham M, Bachelez H et al (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Derm 74:134–142CrossRefPubMed Rich P, Gooderham M, Bachelez H et al (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Derm 74:134–142CrossRefPubMed
56.
Zurück zum Zitat Goldacker S, Gause AM, Warnatz K, Kommission Pharmakotherapie der DGRh (2013) Vaccination in adult patients with chronic inflammatory rheumatic diseases. Z Rheumatol 72:690–704CrossRefPubMed Goldacker S, Gause AM, Warnatz K, Kommission Pharmakotherapie der DGRh (2013) Vaccination in adult patients with chronic inflammatory rheumatic diseases. Z Rheumatol 72:690–704CrossRefPubMed
57.
Zurück zum Zitat Krüger K, Albrecht K, Rehart S et al (2014) Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur perioperativen Vorgehensweise unter Therapie mit DMARD und Biologicals bei entzündlich-rheumatischen Erkrankungen. Z Rheumatol 73:77–84CrossRefPubMed Krüger K, Albrecht K, Rehart S et al (2014) Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur perioperativen Vorgehensweise unter Therapie mit DMARD und Biologicals bei entzündlich-rheumatischen Erkrankungen. Z Rheumatol 73:77–84CrossRefPubMed
58.
Zurück zum Zitat Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5CrossRefPubMedPubMedCentral Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5CrossRefPubMedPubMedCentral
Metadaten
Titel
Psoriasisarthritis
Übersicht medikamentöser Therapieoptionen und Anwendungsbesonderheiten
verfasst von
F. Behrens
D. Thaçi
Prof. Dr. J. Wollenhaupt
K. Krüger
Publikationsdatum
01.06.2016
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 5/2016
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-016-0110-6

Weitere Artikel der Ausgabe 5/2016

Zeitschrift für Rheumatologie 5/2016 Zur Ausgabe

Einführung zum Thema

Osteoporose

Mitteilungen der DGRh

Mitteilungen der DGRh